Overdose : how excessive government regulation stifles pharmaceutical innovation / Richard A. Epstein.
By: Epstein, Richard Allen.
Contributor(s): Yale University. Institute for Policy Innovation.
New Haven, CT ; London : Yale University Press, 2008Description: xi, 283 p. ; 24 cm.ISBN: 9780300143263 (hbk.).Subject(s): United States. Food and Drug Administration | Pharmaceutical industry -- Government policy -- United States | Political planning -- United States | Government regulation -- United StatesGenre/Form: Print books.| Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|
| On Shelf | HD9666.6 .E68 2008 (Browse shelf) | Available | AU0000000006376 |
Browsing Alfaisal University Shelves , Shelving location: On Shelf Close shelf browser
|
|
|
|
|
|
|
||
| HD9665.5 .T46 2016 Therapeutic revolutions : pharmaceuticals and social change in the twentieth century / | HD9666.4 .R58 2023 Capitalizing a cure : how finance controls the price and value of medicines / | HD9666.5 .D86 2012 Drugs for life : how pharmaceutical companies define our health / | HD9666.6 .E68 2008 Overdose : how excessive government regulation stifles pharmaceutical innovation / | HD9666.94 .K444 2021 Empire of pain : the secret history of the Sackler dynasty / | HD9675.O643 U64 2022 American cartel : inside the battle to bring down the opioid industry / | HD9675.V334 M645 2022 The messenger : Moderna, the vaccine, and the business gamble that changed the world / |
"An Institute for Policy Innovation Book."
Includes bibliographical references and index.
Rising expectations and diminishing returns -- Property generally : externalities, coordination, and the public domain -- Intellectual property: the public domain and private rights -- Taming conflict of interests -- Federally sponsored research under Bayh-Dole -- The anticommons -- The single monopoly : current patent limitations -- Rate regulation : an unneeded swamp -- Patent purchases: a second swamp -- Socialization of R&D : the final swamp -- The steady expansion of FDA power -- FDA versus the individual : upstream or downstream decision making -- Drug withdrawa l : too much, too soon -- Getting the drugs to market -- Deceptive marketing -- Tort preliminaries -- Product liability for prescription drugs : manufacturing and design cases -- The main event : misrepresentation, overpromotion, and duty to warn -- Conclusion : socialized medicines.